P.136 Heart transplantation following medically assisted dying using ex situ normothermic machine perfusion
Dr. Michael J O'Leary, Australia
P.433 Bridge to heart transplantation: Preoperative etiology, intraoperative anesthesia management and postoperative follow-up findings and complications in patients with heart support device
Atilla Sezgin, Turkey
P.500 The first experience of Inclisiran treatment after heart transplantation
Dr. Maria Simonenko, Russian Federation
P.502 Use Of The lntra-Aortic Balloon Pump As A Bridge To Transplant: Still A Very Good Option - 10 Years Of Experience ln The Largest Heart Transplant Center ln Brazil
Dr. Ronaldo H B Santos, Brazil
P.503 The Importance of a Brazilian Specialized Transplant Center in a High-Complexity University Hospital: an 11 years overview of the outcomes.
Dr. Ronaldo H B Santos, Brazil
P.504 The Suicide Heart: Primary Graft Dysfunction and Mortality after Heart Transplantation
Dr. Ronaldo H B Santos, Brazil
P.505 Multimorbidity and complexity of treatment in the long term after heart transplantation.
Dr. Nadezhda Koloskova, Russian Federation
P.506 Outcome of Heart Transplant in a Young Patient referred with Cardiogenic Shock and Multi-organ Failure
Dr. Fatemeh Mohammad, United Arab Emirates
P.507 Donor and Recipient Risk Assessment in Heart Transplantation at a Reference Center in Latin America and Its Influence on Clinical Outcomes.
Dr. Ronaldo H B Santos, Brazil
P.508 Heart transplantation in pediatric patients with restrictive cardiomyopathy
Dr. Murat Ozkan, Turkey
P.509 Comparison of normal and low preoperative right ventricular function in terms of acute renal failure in patients implanted with a left ventricular assist device
Dr. Deniz Sarp Beyazpinar, Turkey
P.510 A study in heart transplant patients: Especially class-II anti-HLA antibodies may remain persistent
Dr. Begum Yavascaoglu Uney, Turkey
P.512 Malignancy after lung transplantation
Graciela Svetliza, Argentina
P.513 Pregnancy in lung transplant recipients
Graciela Svetliza, Argentina
P.514 Clinical utility of 1:16 serum dilution as a predictor of response to therapeutic plasma exchange for HLA antibody-mediated rejection treatment and overall survival in lung transplant recipients: A two center study
Dr. Mohamed Elrefaei, United States
P.515 ICU-Acquired Muscle Weakness in COVID-19 Lung Transplant Cases: The Imperative for Enhanced Surveillance and Prophylaxis
Juan Chen, People's Republic of China
P.516 Correlation of pre and immediate post-transplant factors with initial dd-cfDNA% in patients in a surveillance protocol
Dr. Renata Ponsirenas, United States
P.517 Evaluation of Donor-Derived Cell-Free DNA (dd-cfDNA) levels in Primary Graft Dysfunction (PGD) After Lung Transplantation